242 related articles for article (PubMed ID: 28356064)
1. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
[TBL] [Abstract][Full Text] [Related]
2. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
[TBL] [Abstract][Full Text] [Related]
3. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
4. Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
Popp MC; Klippstein M; Lohneis P; Kalinski T; Li J; Quaas A; Bludau M; Wang Z; Waldschmidt D; Kunzmann V; Damanakis A; Gebauer F; Zhao Y; Bruns CJ; Popp FC
Pancreas; 2020; 49(10):1307-1314. PubMed ID: 33122518
[TBL] [Abstract][Full Text] [Related]
5. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
6. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
7. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
[TBL] [Abstract][Full Text] [Related]
9. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
[TBL] [Abstract][Full Text] [Related]
10. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
Singhi AD; Foxwell TJ; Nason K; Cressman KL; McGrath KM; Sun W; Bahary N; Zeh HJ; Levy RM; Luketich JD; Davison JM
Am J Surg Pathol; 2015 Apr; 39(4):487-95. PubMed ID: 25634752
[TBL] [Abstract][Full Text] [Related]
11. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.
Pen SL; Shan YS; Hsiao CF; Liu TW; Chen JS; Ho CL; Chou WC; Hsieh RK; Chen LT; Ch'ang HJ
Radiother Oncol; 2021 May; 158():146-154. PubMed ID: 33667587
[TBL] [Abstract][Full Text] [Related]
12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
13. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
Khorana AA; Hu YC; Ryan CK; Komorowski RA; Hostetter G; Ahrendt SA
J Gastrointest Surg; 2005; 9(7):903-11. PubMed ID: 16137582
[TBL] [Abstract][Full Text] [Related]
16. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
19. Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling.
Yamamoto KN; Yachida S; Nakamura A; Niida A; Oshima M; De S; Rosati LM; Herman JM; Iacobuzio-Donahue CA; Haeno H
Cancer Res; 2017 Jun; 77(12):3325-3335. PubMed ID: 28381541
[TBL] [Abstract][Full Text] [Related]
20. SOX9 expression predicts relapse of stage II colon cancer patients.
Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
